Relevant to the human disease, the protective effect of IFN-β, first-line therapy in relapsing–remitting multiple sclerosis, in patients with MS, was attributable to IL-27 induction, which promotes the production of IL-10 by dendritic cells [65,66]. Here, IL27 is linked to myeloid sarcoma.